The first human genome was sequenced in 2001 at a cost of $3 billion. Today, human genome sequencing costs less than $1000, and in a few years the price will drop below $100. Thus, personal genome sequencing will soon be widely adopted as it enables better diagnosis, disease prevention, and personalized therapies. Furthermore, if genomic data is shared with researchers, the causes of many diseases will be identified and new drugs developed. These opportunities are creating a genomic data market worth billions of dollars.
Our highest priority at Nebula is ensuring that YOU and only YOU get to decide how you want your data to be used. Visit our new blog to read more about the unique ways we help you control and protect your data. #DataPrivacy #SpitWithPurpose https://t.co/pc23hfCPcU
Incidence of #asthma is disproportionately high in those of #African descent, but their genomes are underrepresented in studies. A new study using genomes of people w/ AF ancestry found new genetic variations associated w/ asthma in people of AF descent. https://t.co/QnBH1wYX0M
The genome of the #GreatWhiteShark has been sequenced for the first time! They've been around for almost 16 mil years and have more advanced #DNA repair mechanisms than humans. Understanding these mechanisms could be useful in the fight against #cancer🐬🔍 https://t.co/rcqCamgexu
On the @FutureTechHeal1 podcast, Nebula CEO @ObbadKamal discusses issues with the current landscape of genomic data, such as how consumers generate data but are not compensated for it, and how Nebula aims to address these issues.